Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Haleon PLC ( (GB:HLN) ) has provided an announcement.
Haleon plc said its trading statement for the first quarter of 2026, covering the period to 31 December 2026 year-end, has been published and is now available to investors via the London Stock Exchange’s document service and the company’s own website. The disclosure ensures shareholders and analysts have access to the group’s latest financial and operational performance data as it navigates the consumer health market.
The company is also hosting a results presentation and Q&A session for analysts and shareholders, led by Chief Executive Brian McNamara and Chief Financial Officer Dawn Allen and accessible via webcast. By pairing detailed financial disclosure with direct engagement, Haleon aims to strengthen transparency with capital markets and reinforce its positioning as a focused, standalone consumer health player.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.15 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC
Haleon plc is a consumer health company focused on improving everyday health through a broad portfolio of over-the-counter products. Its brands span six key categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health, with well-known names such as Sensodyne, Panadol, Voltaren and Centrum serving more than one billion consumers worldwide.
Average Trading Volume: 21,724,389
Technical Sentiment Signal: Sell
Current Market Cap: £31.14B
For detailed information about HLN stock, go to TipRanks’ Stock Analysis page.